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ABSTRACT OF THE DISSERTATIONs
Genomic Contributors to Individual Differences in Reward-Related Neural Activity
by
Lindsay Jane Michalski
Doctor of Philosophy in Psychological & Brain Sciences
Washington University in St. Louis, 2019
Professor Ryan Bogdan, Chair
Aberrant reward-related behavior, including impulsive and risk-taking behaviors, is a common
feature of externalizing psychopathology (e.g., attention deficit hyperactivity disorder, antisocial
personality disorder, and substance-use disorders). Through imaging studies, these behaviors
have been linked to dysregulated reactivity within a diffuse reward-related corticostriatal neural
network, including the striatum, frontal regions (namely orbital, ventromedial, and dorsolateral
cortices), the insula, and the hippocampus. Because variability in risk-taking behavior and
related psychopathology is moderately-to-largely heritable (i.e., with estimates ranging from 40 –
80%), a genetically-informed approach is well-positioned to provide valuable insight into the
etiology of reward-related neural and behavioral phenotypes that characterize externalizing
psychopathology. Using summary statistics from a recent genome-wide association study
(GWAS) of risk tolerance among 939,908 individuals, we generated polygenic risk scores (PRS)
for a European-ancestry subsample (usable data ranging from n=457 to n=518; see Table 2) of
the Duke Neurogenetics Study (DNS; a large community sample) and examined associations
between genomic liability and risk-taking phenotypes (i.e., self-reported impulsivity and alcohol
use, and behavioral delay discounting), as well as BOLD activation of the ventral striatum.
Contrary to our hypotheses, GWAS-based PRS were not consistently significantly associated
vi

with risk-related behavior or with activation of the ventral striatum. In order to increase
biological informativeness, we also used PrediXcan analyses to identify genes with differential
expression based on the risk-related genomic liability; however, PRS of these differentiallyexpressed variants were also not significantly associated with risk-related behavioral or neuralactivation phenotypes in the DNS. Though these null findings may reflect a true lack of
association between risk-related genetic liability and behavior/neural externalizing phenotypes,
we discuss possible alternative explanations regarding imprecise phenotyping in the discovery
GWAS, inadequate statistical power, and questionable reliability of task-based fMRI
measurements.

vii

1.0 Introduction
Externalizing psychopathologies (e.g., ADHD, antisocial personality disorder, substance use
disorders) are characterized by impulse-control problems, sensation-seeking behaviors, poor
interpersonal functioning, and psychopathic traits that lead to significant adverse effects on
social relationships, overall health, and quality of life. Externalizing disorders are common and
often diagnosed in early life, with conduct and oppositional defiant disorders affecting up to 10%
of youth and ADHD affecting roughly 10-17% of youth and adolescents (Hicks, Krueger,
Iacono, McGue, & Patrick, 2004; Larsson, Chang, D’Onofrio, & Lichtenstein, 2014).
Furthermore, externalizing behaviors that initially manifest in childhood often persist into
adulthood (e.g., impulsive behavior, risk-taking, and attention deficits; Rodgers et al., 2015) and
are associated with substance use disorders, mood and anxiety disorders, and other negative
outcomes, including failure to complete high school, early pregnancy, and criminality (Reef et
al., 2011; Loth et al., 2014).
Externalizing behavior and related psychopathology also have a tremendous
socioeconomic impact on society. For example, in 2010, alcohol use cost the federal, state, and
local governments in the United States $249 billion; this equates to $2.05 per alcoholic beverage
consumed, or an annual cost of $807 per person (Sacks, Gonzales, Bouchery, Tomedi, & Brewer,
2015). These costs can be primarily attributed to lost workplace productivity, while the
remainder is due to health care, law enforcement, and motor vehicle accidents. Similarly, the
literature suggests that other forms of externalizing behavior also pose a significant burden: for
example, ADHD is estimated to contribute $143-266 billion in annual socioeconomic costs
(Doshi et al., 2012). Altogether, estimates suggest that externalizing behavior and related
1

psychopathology cost the US government more than $700 billion annually (Caulkins, Kasunic, &
Lee, 2014; Doshi et al., 2012; Kessler et al., 2009).
The widespread prevalence and astronomical costs of externalizing psychopathology are
starkly contrasted by our limited etiologic knowledge of how these disorders arise and persist.
Though etiologic factors associated with externalizing psychopathology remain unidentified
(with few exceptions, e.g., the role of variation in alcohol metabolism in problematic alcohol use;
Köhnke, 2008; Edenberg and Foroud, 2014), recent genetic-association and neuroscience studies
do offer some clues. First, externalizing behavior and psychopathology are moderately-to-largely
heritable (i.e., 49-88%; Larsson et al., 2014; Verhulst, Neale and Kendler, 2015), suggesting that
genetic variation plays a prominent role in their expression. Consistent with high rates of
comorbidity (Vollebergh et al., 2001), twin studies show significant genetic overlap across
externalizing disorders (Krueger et al., 2002; Slutske et al., 1998), further suggesting common
mechanisms that may underlie the broad spectrum of externalizing behaviors despite diagnostic
distinctions that imply unique etiology. Second, neuroimaging research has repeatedly linked
externalizing behavior and psychopathology to variability in reward-related brain function.
However, the neural mechanisms through which genetic risk may contribute to externalizing
behavior have not yet been thoroughly investigated. Understanding the neural mechanisms of
genomically-conferred risk for externalizing behaviors that are common to antisocial/conduct
disorders, ADHD, and substance-use disorders alike may ultimately lead to refined nosology,
prevention, intervention, treatment, and public-policy considerations that honor a complex
etiologic architecture.

2

1.1

The Heritability of Externalizing Behavior and Psychopathology

Twin studies show that externalizing disorders are highly heritable (49–88%; Slutske et al.,
2008; Jacobson et al., 2002; Fu et al., 2002), with ADHD being among the most heritable
psychiatric disorders (alongside schizophrenia and bipolar disorder, with estimates up to 88%;
Larsson et al., 2014). Furthermore, both twin (Hicks et al., 2004) and epidemiologically-based
studies (Krueger et al., 2002) indicate high genetic overlap across related externalizing disorders,
suggesting that common genetic factors largely contribute to a broad externalizing factor rather
than acting independently to impart liability for specific diagnoses. In fact, a general
externalizing liability factor is highly (i.e., 80%) correlated between relatives, and associations
between impulse-control issues in parents and externalizing behaviors (e.g., antisocial
phenotypes) in their children are largely due to shared genetic – rather than environmental –
influences (Button et al., 2009; Hicks et al., 2004; Hicks, South, DiRago, Iacono, & McGue,
2009). Taken together, these insights suggest that it is crucial to better understand the
mechanisms that may underpin genetic contributions to the persistence of externalizing
behaviors generally defined within families and across generations.

1.2

Methods of Characterizing Genetic Risk

Candidate-gene and Genome-wide Studies
Thus far, molecular genetics research on externalizing psychopathology and reward-related brain
function has largely focused on single variants within candidate genes (e.g., MAOA; dopaminesystem genes including DRD2 and DRD4; Weeland et al., 2015). However, mounting evidence
suggests instead that complex behavior and neural phenotypes are undergirded by extensive
polygenicity, with common variants conferring only small effects that require large samples to
detect. As a result, use of the single-variant, candidate-gene approach has become increasingly
3

controversial and, consequently, has been largely abandoned in mainstream genetics. Moreover,
while some candidate-gene work on externalizing phenotypes and reward-related brain function
has been successfully replicated [e.g., gene-environment interaction between MAOA variant and
childhood adversity predicting antisocial phenotypes (Byrd & Manuck, 2014); the influence of
several DRD2 variants and the Taq1A variant in ANKK1 on striatal dopamine-receptor binding
potential (Gluskin & Mickey, 2016)], the vast majority is characterized by inconsistent findings
that suggest a high rate of false positives (Pasche & Yi, 2010).
In light of these issues, which limit the utility of candidate-gene studies (Duncan &
Keller, 2011), as well as the realization that psychiatric phenotypes are a product of complex
polygenic architecture, the past decade has seen a surge in genome-wide association studies
(GWAS; Visscher et al., 2012, 2017; Kendler, 2013). Made possible by recent advancements in
technology, associated reductions in cost, and a field-wide push for a more collaborative
approach to science, this shift has led to the acquisition of (previously-unfathomably) large
datasets and, in turn, the identification of novel genetic variants linked to psychopathology and
associated traits. Specific to externalizing phenotypes, GWAS of alcohol-use disorders from the
past decade have consistently implicated genes within the ADH cluster (see: Frank et al., 2012;
Gelernter et al., 2014; Walters et al., 2018) and other GWAS have implicated loci across
externalizing diagnoses [e.g., GABRA2 associated with both conduct phenotypes in children and
substance use in adults (Dick et al., 2006); ABCB1 linked to both substance-use disorders and
antisocial traits in adulthood (Salvatore et al., 2015)].
Polygenic Risk Scores
The era of GWAS has provided two compelling insights. First, associations of common genetic
variation with both psychiatric and neural phenotypes are characterized by small effects that
4

require large samples for detection. Second, and more encouraging, the additive effects of
independent and commonly-occurring variants, when weighted by summary statistics from a
well-powered GWAS in what is called a polygenic risk score (PRS) approach, are reliably
predictive of related constructs (Bogdan, Baranger, & Agrawal, 2018). Briefly, the PRS
approach is informed by large-scale GWAS of thousands of participants that serve as discovery
samples; other large, healthy community samples (i.e., “target” samples) are used for both
replication and extension, wherein PRS are calculated for each participant using statistics from
the original discovery sample. Using odds ratios or beta-weights, depending on the nature (i.e.,
continuous or discrete) of the trait for which the GWAS was conducted, each genetic variant’s
contribution to the total polygenic score is weighted by the strength of its association with the
phenotype-of-interest in the discovery sample. Then, within the target sample, these scores are
used to determine the extent to which variations in genetic liability at the subject level are
associated with a given phenotype (Dima & Breen 2015).

For example, in a sample of

adolescents and young adults, externalizing PRS reliably predicted externalizing diagnoses,
subclinical externalizing behavior, and impulsiveness, indicating that externalizing behaviors
likely precede psychiatric diagnosis in those at high genetic risk (Salvatore et al., 2015b);
further, in a sample of children aged 9-12, ADHD PRS predicted externalizing symptoms and
explained nearly 1% of variance in a broad psychopathology factor (Brikell et al., 2018; Caspi,
Houts, Belsky, & Goldman-Mellor, 2015). Because this innovative technique increases power to
detect small effect sizes relative to single variant approaches, it bolsters the success of replication
attempts and enables researchers to examine links between polygenic risk and psychiatricallyrelevant phenotypes in large cohorts of healthy individuals, which avoids confounding variables
inherent to patient samples (i.e., medication use, comorbidity, disease course, and symptom
5

severity). Furthermore, genotype – and, thus, PRS – is stable across the lifetime, which cannot be
said of other neural, physical, or biological markers that may be considered “predictors” of
disease. Thus, the PRS method is uniquely positioned to improve our understanding of the
mechanisms that underlie externalizing behaviors across diagnostic categories.
In the last year, numerous GWAS of externalizing-related constructs have been
published, the most well-powered of which was conducted by Linner et al. using 939,908 total
participants aggregated from the UK Biobank (n=431,126) and 23andMe (n=508,782) datasets.
This study, which reported 124 independent loci associated with risk-tolerance measured via
responses to a single self-report item, may inform our examination of genetic associations with
reward-related neural function and risk-related behavioral measures.

1.3 Reward-Related Neural Activity: Associations with Externalizing
Behavior and Psychopathology
Reward-related Neural Circuitry
The ventral striatum (VS), a hub of a corticostriatal circuit that is chiefly involved in reward
processing, has been reliably implicated in reward-related behaviors among healthy controls and
patients with psychiatric diagnoses (Hariri, 2009). Within this reward circuit, the VS may be
conceptualized as a “gate,” opening and closing to convey motivation toward goals and allowing
us to initiate action in order to acquire or achieve it. The corticostriatal circuit also includes
several nodes which engage in unilateral and reciprocal connections with the VS hub. The dorsal
striatum (DS), which is divided into two subregions, the putamen and the caudate, is a
downstream target of the VS. Namely, the caudate belongs to an “executive loop” that primarily
projects to the frontal cortex via the thalamus, and allows for formulation of an action plan; the
putamen engages in a “motor loop” that predominantly sends connections between the VS, DS,
6

and motor and premotor cortices and aids in the generation and activation of motor programs to
physically achieve a goal (e.g., picking up a glass and taking a drink). Various frontal regions
also play a significant role in this circuit. These include the orbitofrontal cortex, which is
associated with the assignment of subjective value to options in order to evaluate and choose
between them, and the ventromedial prefrontal cortex, which integrates signals from the
aforementioned regions and modulates motivational impulses received from the VS (Rushworth,
Noonan, Boorman, Walton, & Behrens, 2011). Altogether, this multifaceted circuit is responsible
for our range of responses to reward signals, including anticipating eventual reward receipt,
integrating external environmental and internal subjective awareness to plan actions that will
satisfy our motivations, and initiating the motor actions required to carry out those goal-directed
plans (Haber, 2011; Haber & Knutson, 2010).
Associations with Externalizing Psychopathology
The corticostriatal reward circuit is inextricably linked to impulsiveness, a key externalizing
symptom that is common to ADHD, antisocial and conduct disorders, and substance-use
disorders. In fact, in healthy controls, higher scores on behavioral measures of impulsivity are
correlated with increased levels of VS reactivity to appetitive stimuli, suggesting that VS
activation may generally track with impulsive tendencies (van der Laan, Barendse, Viergever, &
Smeets, 2016; Weiland et al., 2014). Externalizing diagnoses, which may be conceptualized as
the outward manifestation of disordered functioning of the corticostriatal circuit, tend to be
associated with differential VS activation. For instance, impulsive traits are positively correlated
with VS reactivity among antisocial patients (Buckholtz et al., 2010), indicating that antisocial
behaviors may stem from aberrant behavioral control mechanisms. However, psychiatric
extremes of impulsivity do not necessarily follow a stereotypic pattern of increased activation
7

during all stages of reward (i.e., anticipation and receipt). For example, while ADHD and
polygenic risk for its expression have been linked to increased VS response to reward receipt
(Carey, Knodt, Conley, Hariri, & Bogdan, 2017; Von Rhein et al., 2015), dampened VS
activation among ADHD patients during reward anticipation suggests that the VS may fail to
activate externally-prompted downstream motivation-dependent processes that enable focused
goal pursuit (Scheres, Milham, Knutson, & Castellanos, 2007). As such, this may lead to
dysregulated reward-related behavior, independent of long-term (and even short-term) goals.
Meanwhile, substance use disorder – which is defined by cyclical periods of craving/seeking
(i.e., disordered motivation and goal-direction), binging/compulsive use (i.e., disordered
behavioral control mechanisms), and withdrawal – has been linked to increased VS reactivity to
both associated conditioned stimuli (e.g., drug paraphernalia) and delivery of the preferred
substance, as well as deficient top-down prefrontal modulation of the reward circuit (Kober et
al., 2010). Taken together, these findings highlight a key role of the VS in externalizing behavior
and psychopathology.

8

1.4

The Current Study

Given evidence that common genetic factors contribute to a continuum of externalizing-related
constructs (Dick et al., 2008), rather than to singular diagnostic categories specifically, the
current study examines whether genetic variants linked to risk-taking behavior predict 1) rewardrelated brain function and 2) behavioral markers of risk-taking and impulsiveness.1 In light of the
limited utility of single-variant analyses – as they do not capture the polygenic architecture of
complex behavior and often explain only a small proportion of variance of complex traits (Dima
& Breen, 2015; Ferreira et al., 2008; Sullivan, 2010) – a polygenic risk score (PRS) approach is
employed here to leverage genetic risk across the genome, which can account for much larger
proportions of phenotypic variance (Lee, Wray, Goddard, & Visscher, 2011). The PRS method is
well-positioned to detect neuroimaging phenotypes associated with psychiatric disorders at small
effect sizes, which is key to expanding our understanding of the etiology of complex disease.
Further, as discovery sample sizes continue to increase, so does the utility and predictive power
of PRS (Dima & Breen 2015); thus, a potential strength of the Linner et al. risk-taking GWAS is
its sample size of more than 900,000 participants, though we must also consider the possible
implications of a single-item phenotype used to delineate risk-taking behavior. Importantly, in
isolation, the PRS approach does not provide insight into the mechanisms underlying any
emerging associations between genotype and externalizing phenotypes, and its predictive
capacity for brain-based phenotypes may be limited by the inclusion of other contributors (e.g.,
variants affecting peripheral arousal).

1

Given null findings (see Results), as well as recent literature pointing to questionable reliability of taskrelated fMRI (Elliot et al., 2019; see Discussion), we further probed whether risk-taking PRS are
associated with variability in brain structure phenotypes. As these analyses were not planned in the
original dissertation, they are presented in Supplemental Tables 2 and 3 and discussed only briefly.
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Variability in brain-based gene expression may be another key mechanistic contributor
to both the etiology and heritability of psychiatric diagnoses and related phenotypes (Nicolae et
al., 2010; Gusev et al., 2014). Given this, we also examined whether genomically-associated
differences in gene expression are correlated with risk taking, and, if so, whether polygenic
variation within these differentially-expressed genes is correlated with reward-related brain
function and behavior (Gamazon et al., 2015). To do so, we used PrediXcan software: this
program imputes static-DNA-related differences in brain-based gene expression using postmortem gene expression and DNA genotyping; as such, it allows us to test whether such
differences in gene expression are correlated with genomic liability for risk-tolerance based on
the Linner et al. GWAS (2019). Following these imputation-based analyses, we then computed a
PRS based on PrediXcan-identified gene to investigate whether integrating gene expression data
may improve the predictive utility of PRS for neural phenotypes.
Together, the PRS and PrediXcan methods allow us to better characterize the temporal
contribution of genetic influences on phenotypic outcomes: that is, whether psychiatric neural
phenotypes arise due to predisposing genomic factors or, rather, as a consequence of behavioral
expression or its correlates. The current study uniquely leverages a large community sample (the
Duke Neurogenetics Study) to contribute to this etiological understanding while working within
the multifaceted genetic and phenotypic architecture of externalizing psychopathology. It is
important to keep in mind, however, that the nature of phenotypic assessment required to attain
large sample sizes – as in the Linner et al. GWAS upon which we are drawing – is necessarily
broad, and therefore may sacrifice specificity. In light of this, the current study also attempts to
disentangle potential strengths and limitations by comparing the predictive power of GWASderived PRS to a more biologically-informed gene-expression-based PRS. We hypothesized that
10

PRS based on the Linner et al. risk-tolerance GWAS will be associated with differential VS
activation, as well as risk-related behavior (i.e., increased self-reported impulsivity, delay
discounting, and problematic alcohol use) in our community sample. We also hypothesized that
PrediXcan analyses will identify genetic variants that impart differential gene expression based
on genomic liability for risk-tolerance. Further, because of its improved biological relevance, we
hypothesize that PrediXcan-based PRS will outperform GWAS-based PRS and be more strongly
associated with both brain activation and behavioral measures of risk-taking.

11

2.0 Methods
2.1

Sample: The Duke Neurogenetics Study

The Duke Neurogenetics Study (DNS) assesses a wide range of behavioral, experiential, and
biological phenotypes among young-adult (18–22-year-old) college students. Self-report,
neuroimaging, and genomic data are available from 526 non-Hispanic participants of European
ancestry. Ancestry was determined via self-report and confirmed using ancestrally informative
principal components derived from genomic data (no individuals were ±6 SDs from the mean on
the top 10 components; Purcell et al., 2007) Following quality control, 34 individuals were
excluded from fMRI analyses (see Table 1 for specific exclusions), leaving a final sample of 492
(mean age=19.80±1.23; 234 males) participants of European ancestry for functional analyses
(see Table 2 for further information on this sample). Each participant provided written informed
consent to a protocol approved by the Duke University Medical Center Institutional Review
Board prior to participation and received $120 remuneration. All participants were in general
good health and free of exclusion criteria specific to this study, including: (1) medical diagnosis
of cancer, stroke, diabetes requiring insulin treatment, chronic kidney or liver disease, or lifetime
psychotic symptoms; (2) use of psychotropic, glucocorticoid, or hypolipidemic medication; (3)
conditions affecting cerebral blood flow and metabolism (e.g., hypertension); and (4)
contraindications to MRI scanning. DSM-IV Axis I and select Axis II (i.e., borderline and
antisocial personality disorder) psychiatric disorders were assessed with the electronic Mini
International Neuropsychiatric Interview (Sheehan et al., 1998) and Structured Clinical Interview
for the DSM-IV Axis II (SCID-II; see Supplemental Table 1; First et al., 1996).

12

Table 1. DNS Exclusion Criteria

Exclusion Reason
Scanner related artifacts in fMRI data
Movement outliers
Inadequate signal in regions of interest
Poor behavioral performance
Incomplete data collected from task
Incidental structural brain abnormalities

Number of Participants (% of n=492)
4 (0.01%)
9 (0.02%)
10 (0.02%)
5 (0.01%)
4 (0.01%)
2 (0.02%)

Table 2. DNS Sample Data
Variable
Sex
Presence of any psychiatric diagnosis*
Age
Left VS reactivity (n=457)
Right VS reactivity (n=457)
BIS score (n=496)
DDT score (n=496)
AUDIT score (n=494)

Number of Participants (% of n=492)
234 males (47.5%)
131 participants (26.6%)
Mean ± SD
19.80 ± 1.23
0.0522 ± 0.0522
0.0514 ± 0.1621
60.7527 ± 8.7766
-2.7022 ± 0.7972
6.0084 ± 4.3791

*Breakdown of specific diagnostic categories is supplied in Supplemental Table 1

2.2

Self-Report and Behavioral Measures of Risk-Taking

Delay Discounting
Delay discounting tasks assess preferences for varying amounts of money contingent upon
whether they are delivered immediately or after a specified amount of time. Both the amount of
money and the delay before receipt are varied such that we can calculate participant
“indifference points,” i.e., the likelihood of choosing a smaller reward delivered immediately
versus a larger reward delivered after a delay. A consistent preference for a smaller reward
received sooner is associated with impulsivity (Green, Myerson, & Vanderveldt, 2014). In the
DNS, delay discounting is assessed as follows: immediate reward amounts are varied from $0.10
13

to $105. The waiting period for delayed reward (valued at a constant $100) is varied from 0 days
to 5 years (in intervals of 0, 7, 30, 90, 180, 365, or 1825 days; Nikolova et al., 2016). Then, as a
summary measure, we computed area-under-the-curve measurements of discounting for each
participant (Myerson, Green, & Warusawitharana, 2001). This method is both reliable and
flexible, as it does not assume any specific form of the discounting function.
Impulsivity
To examine trait impulsivity, the DNS uses the Barratt Impulsiveness Scale (BIS), a self-report
measure that assesses impulsivity as a behavioral construct / personality trait with good internal
consistency (α=0.84; M=61.78; SD=9.41; range: 37-113; Barratt and Patton, 1995).
Substance Use
The DNS examines potentially-problematic alcohol use using the Alcohol Use Disorders
Identification Test (AUDIT), a 10-item self-report questionnaire that gathers information on
consumption and behavioral tendencies (Saunders et al., 1993).
Scores range from 0-40, with scores >7 indicating hazardous drinking and >20 indicating alcohol
dependence. This measure has been reported to have good internal consistency across diverse
samples and settings (median reliability coefficient of 0.83; Reinert & Allen, 2007).

2.3

Functional Magnetic Resonance Imaging Protocols

Reward-Related Behavior Paradigm
A number-guessing paradigm was used to elicit ventral striatum reactivity. This block-design
paradigm consists of three blocks of predominantly positive feedback (80% correct guess; gain
feedback), three blocks of predominantly negative feedback (80% incorrect guess; loss feedback)
14

and three control blocks (displaying a yellow circle after each response; Delgado et al. 2000,
Hariri et al. 2006). Blocks are presented in pseudo-random order and are composed of five trials
each. During each trial of the positive and negative feedback blocks, participants are given 3 s to
guess via button press whether the value (between 1–4 or 6–9) of a card presented face-down is
higher or lower than 5. The numerical value of the card is then presented for 500 ms, followed by
an arrow indicating positive (green upward-facing arrow) or negative (red downward-facing
arrow) feedback for 500 ms. Finally, a neutral crosshair is presented for 3 s, such that the total
trial length is 7 s. One incongruent trial (e.g. a negative-feedback trial within a predominantly
positive block) was included within each block to maintain task engagement and motivation and
prevent participants from anticipating trial feedback. Three control blocks are interleaved
between the six experimental card-guessing blocks, during which participants are instructed to
make button presses during the 3-s presentation of an ‘x,’ which is then followed by an asterisk
and a yellow circle (presented for 500 ms each). Participants were unaware of the fixed outcome
probabilities and were led to believe that their performance would determine their net monetary
gain. All subjects received $10 upon completion of the task.
BOLD fMRI Data Acquisition
Participants were scanned at the Duke-UNC Brain Imaging and Analysis Center using a
research-dedicated GE MR750 3T scanner equipped with high-power high-duty-cycle 50-mT/m
gradients at 200 T/m/s slew rate, and an eight-channel head coil for parallel imaging at high
bandwidth up to 1 MHz. BOLD fMRI were acquired using a semi-automated high-order
shimming program in order to ensure global field homogeneity. A series of 34 interleaved axial
functional slices aligned with the anterior commissure-posterior commissure (AC-PC) plane
were acquired for full-brain coverage using an inverse-spiral pulse sequence to reduce
15

susceptibility artifact [TR/TE/flip angle = 2000 ms/30 ms/60; FOV=240 mm; 3.75×3.75×4 mm
voxels; interslice skip=0]. Four initial RF excitations were performed (and discarded) to achieve
steady-state equilibrium. High-resolution three-dimensional structural images were acquired in
34 axial slices co-planar with the functional scans (TR/TE/flip angle=7.7 s/3.0ms/12; voxel
size=0.9×0.9×4 mm; FOV=240 mm, interslice skip=0) to allow for spatial registration of each
participant’s data to a standard coordinate system.
BOLD fMRI Data Preprocessing
Individual subject data were realigned to the first volume in the time series to correct for head
motion before being spatially normalized into the standard stereotactic space (Montreal
Neurological Institute (MNI)) template using a 12-parameter affine model (final resolution of
functional images=2 mm isotropic voxels). Next, data were smoothed to minimize noise and
residual difference in gyral anatomy with a Gaussian filter, set at 6-mm full-width at halfmaximum. Voxel-wise signal intensities were ratio normalized to the whole-brain global mean.
To

determine

movement,

the

ARTifact

Detection

Toolbox

(http://www.nitrc.org/projects/artifact_detect; (Mazaika et al., 2007) was used to generate
regressors accounting for images due to large motion (i.e. >0.6mm relative to the previous time
frame) or spikes (i.e., global mean intensity 2.5 standard deviations from the entire time series).
Individual whole-brain BOLD fMRI volumes meeting at least two criteria were flagged and
regressed out when determining task-specific effects: 1) significant mean-volume signal intensity
variation (i.e., within volume mean signal greater or less than 4 standard deviations of mean
signal of all volumes in time series), and 2) individual volumes where scan-to-scan movement
exceeded 2 mm translation or 2º rotation in any direction. Participants with 5% or more
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acquisition flagged volumes per task run were removed from analysis. An ROI mask (AAL
template) from WFU pickatlas (Maldjian, Laurienti, Kraft, & Burdette, 2003) was used to ensure
adequate BOLD signal. Participants who had less than 90% coverage were excluded from
analyses.

2.4

Genotype and Gene Expression Data

DNA Collection and Genotyping
DNA was isolated from saliva derived from Oragene DNA self-collection kits (DNA Genotek)
customized for 23andMe (www.23andme.com). DNA extraction and genotyping were performed
through 23andMe by the National Genetics Institute (NGI), a CLIA-certified clinical laboratory
and subsidiary of Laboratory Corporation of America. One of two different Illumina arrays with
custom content was used to provide genome-wide SNP data, the HumanOmniExpress or
HumanOmniExpress-24 (Hu et al., 2016). Relatedness was assessed using pairwise identity by
descent estimation in Plink 1.07; pairs with a PI_Hat greater than 0.20 had one member excluded
from analyses (n=2). Genotype imputation was performed on all DNS participants with genomewide chip data using the prephasing/imputation stepwise approach implemented in
SHAPEIT/IMPUTE2 (Delaneau, Marchini, & Zagury, 2011; Howie, Fuchsberger, Stephens,
Marchini, & Abecasis, 2012). Imputation was run separately for participants genotyped on the
Illumina HumanOmniExpress and the Illumina HumanOmniExpress-24 arrays using biallelic
SNPs only, the default value for effective size of the population (20,000), and chunk sizes of 3
Mb and 5 Mb for the respective arrays. Within each array batch, genotyped SNPs used for
imputation were required to have missingness <.02, Hardy-Weinberg equilibrium p > 10-6, and
minor allele frequency >.01. The imputation reference set consisted of 2504 phased haplotypes
from the full 1000 Genomes Project Phase 3 data set (May 2013, >70 million variants, release
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"v5a"). Imputed SNPs were retained if they had high imputation quality (Info >.9), low
missingness (<5%), and minor allele frequency (MAF) >.01.
Polygenic Risk Score Calculations
Polygenic risk scores (PRS) were derived using PLINK (Purcell, 2017), across ten p-value
significance thresholds (PT; i.e., 0.0001, 0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, and 1.0) from
the Linner et al. 2019 GWAS of risk tolerance. SNPs were required to have a MAF of >0.02,
genotyping rates of >0.98, and HWE p-values >10−6 to be included in the PRS. SNPs within the
major histocompatibility complex (MHC; present on chromosome 6) were excluded, due to
complex linkage structure within this region. All remaining SNPs were pruned based on linkage
disequilibrium (LD; i.e., genetic correlation) using a p-value-informed method, called
“clumping,” which groups correlated SNPs together and preferentially prunes markers that are
less-significantly associated with the phenotype at hand; this process is implemented in PLINK
to preserve the predictive accuracy of PRS. At all 10 p-value thresholds, each participant had a
single PRS score that reflects genome-wide liability for risk-taking, calculated using beta weight
for risk-taking for each component SNP (i.e., those in the original meta-analysis with p-values
below the cutoff threshold), multiplied by the number of reference alleles for that SNP, then
aggregated and divided by the total number of contributing SNPs.
Discovery GWAS Risk Taking Phenotyping
The Linner et al., 2019 GWAS assessed risk tolerance via a single-item, self-report measure. The
measure was unique to each of the two studies from which the 939,908 participants were drawn.
Participants acquired from the UK BioBank (n=431,126) answered the following: “Would you
describe yourself as someone who takes risks? Yes/No,” where “yes” was coded as a 1 and “no”
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coded as a 0 (mean response ± SD: 0.26 ± 0.44). Participants acquired from 23andMe
(n=508,782) self-rated overall comfort with taking risks on a scale with the following options:
[1] Very uncomfortable / [2] Somewhat uncomfortable / [3] Neither comfortable nor
uncomfortable / [4] Somewhat comfortable / [5] Very comfortable (mean rating ± SD: 3.16 ±
1.15; Karlsson Linnér et al., 2019).
PrediXcan Analyses
We used PrediXcan to examine whether genomic risk for risk taking is correlated with brainbased gene expression. This approach uses postmortem gene expression and static-DNAsequence data from the Genotype-Tissue Expression (GTEx) Project (Lonsdale et al., 2013) to
estimate genomic influence on gene expression and examine whether such genetically-related
differences in gene expression are correlated with a trait of interest based upon GWAS summary
statistics (Gamazon et al., 2015). PrediXcan provides tissue-specific models of 44 tissues from
GTEx, as well as a whole-blood model from the Depression Genes and Networks (DGN) cohort
(Battle et al., 2014), and may help prioritize GWAS-identified loci (Li et al., 2018). Here, we
applied PrediXcan to postmortem brain data to identify specific genes that have differential
expression based on the risk tolerance GWAS (Linner et al., 2019); in effect, the PrediXcan
approach detects significant correlations between imputed gene expression and risk tolerance in
order to identify genes that may play an etiological role in risk-taking behavior. Then, we created
a PRS for each participant that contained variants from these PrediXcan-implicated genes.
PrediXcan-based PRS were computed using the same standards (i.e., MAF, genotyping rates,
HWE, and LD-pruning) and computational methods described above and were weighted based
upon association with the risk-tolerance phenotype (see Polygenic Risk Score Calculations).
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2.5

Statistical Analyses

We performed linear regression analyses using R to test for associations between risk-taking
PRS (at each of ten significance thresholds, i.e., 0.0001 through 1.0) and self-reported risk-taking
measures, as well as activation in the ventral striatum. For these analyses, covariates included
biological sex, age, and the top-three ancestry-informative scaling components to account for
potential effects of population stratification.2

2

For structural analyses, which were performed in light of null functional findings (see Results), we
applied this same linear regression approach with all listed covariates plus average cortical thickness.
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3.0 Results
3.1 Self-Reported Risk-Taking
We observed no significant associations between risk-taking PRS and delay discounting, BIS,
and AUDIT scores [i.e., the only nominally-significant associations arose between PRS at the
0.30 threshold and delay discounting (b=0.7822; p = 0.0172) and between PRS at the 0.0001 and
1.0 thresholds and BIS score (b=0.0961; p = 0.0284 and b=-0.7586; p = 0.0423); all other ps >
0.1129; see Table 3].
Table 3. Main Effects of Risk-Taking PRS on Behavioral Measures

PRS
p-threshold
0.0001
0.001
0.01
0.05
0.1
0.2
0.3
0.4
0.5
1

DDT SCORE

BIS SCORE

β

p

β

-0.0215
-0.0594
-0.0432
0.0281
0.0347
-0.3421
0.7822
0.1624
-0.5826
-0.0772

0.6288
0.4341
0.6042
0.8181
0.8243
0.1129
0.0172
0.7178
0.2751
0.8384

0.0961
-0.0503
0.0659
0.0894
-0.2073
-0.0311
0.1891
0.2264
0.4372
-0.7586

AUDIT SCORE

p

β

p

0.0284
0.4997
0.4220
0.4580
0.1791
0.8838
0.5575
0.6075
0.4047
0.0423

0.0667
0.0819
-0.3474
0.0834
0.0459
-0.0230
-0.4230
0.5589
0.1316
-0.3408

0.1333
0.2797
0.6769
0.4954
0.7709
0.9153
0.1967
0.2122
0.8048
0.3682

3.2 Regional Neural Activation
Consistent with prior work (Delgado, Nystrom, Fissell, Noll, & Fiez, 2000), the card-guessing
task yielded robust bilateral ventral striatal activation (i.e., positive-activation > negativeactivation contrast) that was roughly normally-distributed across participants (see Supplemental
Figure 1). However, while there were sporadic nominal significant associations between PRS at
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individual thresholds (PRS associated with left VS activity at the 0.01 threshold, p = 0.0438;
PRS associated with right VS activity at the 0.01 threshold, p = 0.0222; see Table 4), there were
no consistent significant associations between risk-taking PRS and ventral striatal reactivity
across PRS thresholds (all other ps > 0.110). Of note, Pearson product-moment correlations
computed between bilateral VS activation values and self-reported risk-taking scales show that
only left VS activation and AUDIT score were significantly correlated (r = 0.114, p = 0.007; see
Figure 1); all other correlations were non-significant (all r’s < 0.081, p’s > 0.1065; see Table 5).
Table 4. Main Effects of Risk-Tolerance PRS and Ventral Striatum Activation

PRS
p-threshold
0.0001
0.001
0.01
0.05
0.1
0.2
0.3
0.4
0.5
1

VS ACTIVATION
Left
Right
β
p
β
p
-0.0181
-0.0269
-0.1751
-0.0582
-0.0369
0.0263
0.2555
-0.3788
-0.5892
0.6413

0.6972
0.7327
0.0438
0.6585
0.8232
0.9061
0.4555
0.4139
0.2947
0.1065

-0.0369
-0.0532
0.1986
-0.0191
-0.0914
0.1020
0.1472
-0.1587
-0.5581
0.4411

0.4285
0.4991
0.0222
0.8845
0.5798
0.6467
0.6668
0.7318
0.3205
0.2661

Figure 1. Correlation between Left VS and AUDIT Scores
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Table 5. Pearson Correlations between Ventral Striatum Activation and Self-Report Scales

BIS

DDT

AUDIT

LEFT VS

-0.0203

-0.0178

0.1140*

RIGHT VS

-0.0570

-0.0037

0.0807

*denotes significant correlation at p<0.01

3.3 PrediXcan
Our analyses identified 15 genes that showed differential expression across various tissue types:
CENPV, ZSCAN23, SDCCAG8, AL022393.7, ZSCAN31, XRCC3, BTN3A2, RP5-874C20.3,
FAM184A, ADORA2B, C10orf32, DPYSL5, RP11-62H7.2, ZKSCAN3, THEM6 (all ps <
.0000113; see Table 6). However, PRS computed using SNPs from these 15 genes were not
significantly associated with VS reactivity or behavioral risk-related phenotypes (all ps >
0.0978). GWAS-computed PRS and PrediXcan-computed PRS for each participant were not
significantly correlated (Spearman’s rho = -0.011, p = 0.812).
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Table 6. PrediXcan-Identified Genes with Differential Expression based on Risk-Tolerance
GWAS
TISSUE TYPE(S) WITH
HIGHEST EXPRESSION

β

P

CENPV

Cerebellum

-0.0152

4.81e-08

ZSCAN23

Cerebellum

-0.0153

3.36e-07

SDCCAG8

Diffuse across brain; thyroid

-0.0379

5.63e-07

AL022393.7

Diffuse across brain

-0.0098

6.51e-07

ZSCAN31

Diffuse across brain

-0.0104

1.16e-06

XRCC3

Cerebellum

0.0244

3.69e-06

BTN3A2

Spleen and lymphocytes

0.0127

4.47e-06

Cerebellum

0.0167

5.75e-06

FAM184A

Diffuse across brain

0.0152

6.01e-06

ADORA2B

Frontal regions; nucleus accumbens;
vagina

-0.0398

6.84e-06

C10orf32

Diffuse across brain; adrenal cortex

-0.0109

7.38e-06

DPYSL5

Spinal cord

0.0161

9.62e-06

Thyroid, kidney, lungs

0.0110

9.88e-06

Diffuse across peripheral regions

0.0165

1.03e-05

Cerebellum, frontal cortex, bladder

0.0245

1.13e-05

GENE

RP5-874C20.3

RP11-62H7.2
ZKSCAN3
THEM6
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4.0 Discussion
Externalizing diagnoses, including ADHD, substance-use disorders, and antisocial and conduct
disorders, are moderately-to-largely heritable and characterized by both increased risk-taking
behaviors (i.e., impulsivity, delay discounting, and alcohol use) and differences in neural
activation in key reward-related regions (e.g., ventral striatum). In light of mounting evidence of
a complex polygenic architecture underlying complex behavior and the limited utility of single
SNP and candidate-gene approaches for examining genetic contributions to heritable psychiatric
phenotypes, the current study used a polygenic risk score (PRS) method to assess associations
between risk-related phenotypes and genome-wide liability for risk-taking behavior. Contrary to
our hypotheses, we did not find any consistent significant associations between PRS and neural
activation in the ventral striatum, or between PRS and impulsivity, delay discounting, or AUDIT
scores. Further, though PrediXcan analyses of post-mortem gene-expression data pointed to 15
genes with differential expression related to genomic risk-taking liability, none were
significantly associated with the behavioral or neural phenotypes in question, nor was a PRS
calculated using variants from these genes.
Our null findings run counter to several recent publications showing significant
associations between increased genomic risk for psychopathology and differential neural and
behavioral phenotypes. For example, Erk and colleagues have reported that schizophrenia-based
PRS predicts increased cingulate activation during episodic memory and social-cognition tasks
(Erk et al., 2017), and a systematic review published just this year indicates that, across multiple
studies, genetic liability for bipolar disorder and schizophrenia predicts aberrant activation of
frontal regions (Dezhina, Ranlund, Kyriakopoulos, Williams, & Dima, 2019); together, these
findings putatively link genomic risk to cortical inefficiency during task performance.
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Furthermore, PRS based on cross-diagnostic liability has been linked to increased generalized
risk for substance use, suggesting shared mechanisms between psychopathology and substance
involvement (Carey et al., 2017). PRS computed using genes derived from PrediXcan analyses
showed similar null associations to the GWAS-generated PRS, which suggests that, here, a
biologically-informed approach to PRS did not yield increased predictive power. Notably, no
studies have been published to date utilizing PrediXcan-generated PRS that may reflect
etiological contributions via gene-expression differences, nor have studies been published
comparing predictive power GWAS-generated PRS to that of PrediXcan-informed PRS,
rendering the current study particularly novel. It is possible that predictive power of the
PrediXcan-informed PRS in our study may be limited by potential regulatory factors at play; as
such, it may be useful for future studies to conduct more comprehensive analyses by integrating
further with mRNA-expression databases (e.g., GTEx) to find expression quantitative trait loci
(eQTLs) that are associated with PrediXcan-identified genes (but may be located outside of
them).
Our lack of significant findings may indeed reflect truly null associations; that is, that
genomic liability for risk-taking does not predispose individuals to differences in related neural
or behavioral measures, regardless of whether liability is based upon on statistically- or
biologically-informed associations. However, our null findings may also be attributable to
alternative explanations, which are detailed below.

4.1

GWAS Phenotyping

As noted previously, the Linner et al. GWAS assesses general risk tolerance via a one-item, selfreport measure. Participants acquired from the UK BioBank (n=431,126) answered the
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following: “Would you describe yourself as someone who takes risks? Yes/No,” where “yes”
was coded as a 1 and “no” coded as a 0 (mean response ± SD: 0.26 ± 0.44). Participants acquired
from 23andMe (n=508,782) self-rated overall comfort with taking risks on a scale with the
following options: [1] Very uncomfortable / [2] Somewhat uncomfortable / [3] Neither
comfortable nor uncomfortable / [4] Somewhat comfortable / [5] Very comfortable (mean rating
± SD: 3.16 ± 1.15; Karlsson Linnér et al., 2019). This broad phenotyping has allowed for
consequently high response rates, enabling Linner and colleagues to concatenate data from over
900,000 participants. However, this phenotype is questionably ecologically relevant, and
relatively low endorsement of extreme risk-taking behaviors and attitudes (as surmised from
mean scores on both scales) may indicate that this group is not particularly well-populated with
risk-tolerant individuals. As well, the two datasets that comprise Linner and colleagues’ sample
(i.e., the UK BioBank and 23andMe) used different assessments of risk tolerance, which may
have affected phenotypic continuity across the sample at large. In all, a lack of precision in
phenotypic assessment may have compromised the study’s ability to assess externalizing in a
way that would meaningfully and/or practically correlate with neural or behavioral markers.
Indeed, evidence suggests that phenotyping and sample size may both impact the power
and utility of discovery GWAS (Bogdan et al., 2018). GWAS based on low-pass phenotypic
measurements (i.e., measurements that allow for data to be easily acquired from large samples,
but, in turn, may sacrifice quality or specificity) have successfully identified significant loci: for
example, a GWAS of AUDIT scores, a self-report measure assessing alcohol use in the past 12
months, identifies similar genetic loci and produces results that are genetically correlated with
(rg: 0.33-0.63) with alcohol dependence (Sanchez-Roige et al., 2019). Should we see similar
results for other complex psychiatric phenotypes, it would suggest that low-pass phenotypes,
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such as the metric used by the risk-tolerance GWAS referenced in the current study, may allow
us to quickly amass findings that lend insight into the role of genetic variation in
psychopathology. On the other hand, it is possible that low-pass phenotypes are not positioned to
detect the most mechanistically-informative loci. In fact, some evidence supports the idea that
low-pass phenotyping is not sufficient to uncover the genetic architecture of complex
psychopathology: for instance, in contrast to an initial larger GWAS of major depressive disorder
(Ripke et al., 2012), a smaller GWAS of severe, primarily melancholic, depression characterized
by anhedonia was notably more successful at identifying genomic loci associated with
depression risk, including a previously-reported candidate gene, SIRT1 (Cai et al., 2015).
Meanwhile, other studies using a meta-analytic approach to examine GWAS of heterogenous
depressive phenotypes have identified many variants (Howard et al., 2019; Wray et al., 2018),
e.g., upwards of 100 in a single meta-analysis (see Howard et al., 2019). Going forward, it will
be important for intermediate-phenotype research, such as neuroimaging, to evaluate whether
genomic risk for low-pass phenotypes (e.g., Linner et al., 2019) is differentially predictive than
formal psychiatric diagnoses.

4.2

Reliability of Task-Related fMRI

Our null results may stem from constraints on the precision of our neuroimaging methodology.
In the DNS, VS activation is measured via a canonical card-guessing task: in the scanner,
participants are instructed to guess whether a face-down card will be greater or smaller than a
target number, earning a positive monetary reward for correct guesses and incurring a loss for
incorrect guesses. This task has been shown to reliably elicit robust increases in VS activation to
positive feedback as compared to negative feedback. Notably, task-based fMRI was initially
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developed to measure average regional activation at the group level, in order to identify specific
neural regions associated with phenotypes. Examining whether individual differences in the
extent or variability of activation are associated with complex behavior and psychiatric
phenotypes was intuitively appealing following reliable map-based activation patterns. However,
emerging evidence from meta-analyses and independent studies suggests that the magnitude of
task-related activation as typically studied in individual differences research has poor reliability
as measured via intraclass correlation (ICC; mean ICC=0.39; see: Elliot et al., 2019). This is
based on two converging empirical findings: 1) Across a host of tasks designed to elicit
activation in specific brain regions (included the card-guessing task), target-region reliability
failed to surpass non-target-region reliability, and 2) Using a meta-analytic approach to examine
published task-fMRI findings, test-retest reliability was relatively low (ICC=0.397; Elliot et al.,
2019). Because low reliability necessarily reduces statistical power, this sobering estimate of
task-fMRI reliability for individual-differences research may suggest that previously-published
findings have questionable replicability and validity. Here, it might suggest that task-fMRI is not
the right vehicle with which to identify neural markers of genomic risk or externalizing
disorders, and our null VS-reactivity findings may be the result of employing a method that is
unfit to establish putative links between brain activation and externalizing. Structural MRI may
be better-suited to the individual-differences nature of the current study, as even in betweensubjects research, structural measures yield encouragingly-high test-retest reliability [ICC>0.90;
specifically, cortical thickness and surface area are able to be measured with much greater
reliability than task activation; (Elliot et al., 2019; Han et al., 2006; Jovicich et al., 2006)]. In
light of this, we examined PRS associations with cortical thickness calculated using FreeSurfer.
While estimates were not available for the VS, we examined frontal and sub-cortical regions that
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have been implicated in reward-related processes. These investigations yielded null results as
well (see Supplemental Tables 2 and 3), which may be a product of power and phenotyping
limitations. Of note, we did not use these regions as ROIs for follow-up analyses of task
activation, in part to limit multiple testing, and in part because the ventral striatum is the single
ROI that is most robustly activated during the card-guessing task, while other frontal and subcortical reward-related regions are not activated to nearly the same extent.

4.3

Predictive Power

Critiques of the PRS method have noted that studies are often underpowered to detect small
effects on complex phenotypes (Bogdan et al., 2018). Among PRS computed for psychiatric
diagnoses, those with the greatest predictive power typically predict less than 1% of variance in
psychiatrically-relevant traits. One well-powered schizophrenia PRS (SCZ2-PRS, created by the
Schizophrenia Working Group of the Psychiatric Genomics Consortium, based on a sample of
36,989 cases and 113,075 controls) has been reported to predict 0.7% of variance in negative
symptoms (Jones et al., 2016) and 0.3% of variance in cognition (Riglin et al., 2017) among the
general population. These effect sizes are not particularly encouraging, and the PRS method’s
mixed predictive success is compounded by its reliance on multiple factors, including the PRS
itself (as calculated using summary statistics from a discovery GWAS), the size of the target
sample (i.e., here, the DNS), the nature of the trait it is used to predict, and the true strength of
the association between genomic liability and behavioral or neural phenotypes across diagnoses.
The GWAS on which we based our PRS calculations had an impressive sample of over
900,000 individuals amassed from two large datasets (Karlsson Linnér et al., 2019), which is
more than many previous studies of its kind. However, power calculations (using G*Power
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software) indicate that a target sample size of at least 800 is required to account for a benchmark
1% of variance. Because our target sample, the DNS, has a sample size smaller than this
estimate, it is arguably underpowered to detect effects that may truly exist in the population at
large, which may have led to the null effects we have reported. Further, PRS have been reported
to yield much larger effect sizes when they are used to predict the exact trait on which a
discovery GWAS was based. For instance, estimates suggest that a GWAS for a phenotype with
n = 1,000,000 may generate PRS that explain up to 15% of variance in that same phenotype in an
independent target sample (Rietveld et al., 2013). However, when PRS are used to predict more
distal, related traits – as we have done here to predict neural and behavioral risk-related
phenotypes – they tend to generate smaller effect sizes, which may have also contributed to our
null results.

4.4

Limitations and Future Directions

In all, our results should be considered in the context of several important limitations. Above, we
explored several possible explanations for the null results we report. These included potential
limitations on predictive power, which in the current study stem largely from the relatively-small
sample size of the DNS, despite a quite-large discovery GWAS. In the future, studies with larger
target samples may be better poised to detect small differences in complex externalizing
phenotypes (Bogdan et al., 2018). Further, we discussed the use of task-based fMRI in betweensubjects research, which yields lower reliability than would be needed to detect disorder-related
biomarkers (Elliot et al., 2019). Importantly, the literature recommends a few key actions to
remedy this, including using tailored analyses techniques with existing data (e.g., latent variable
models, machine learning); encouraging open reporting of reliability for all task-fMRI measures
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used to assess individual differences, which will bolster replication attempts; creating new tasks
that prioritize reliable measurement and increase validity; and exposing subjects to complex
stimuli during imaging (i.e., “naturalistic fMRI”), which may maximize ecological validity (for a
more detailed explanation of these points, see: Elliot et al., 2019). Finally, we discussed
imprecise phenotyping in the discovery GWAS that may have limited our study’s practical
applicability. Of note, the discovery GWAS employed a case-control dichotomy of “risk
tolerant” versus “non-risk tolerant” individuals based on a single self-report item. Self-report
measures are especially prone to bias, which may be related to social desirability and
experimenter-expectancy effects, among other factors. Thus. this measurement may have
introduced error to the summary statistics we used to compute PRS. Future genome-wide
explorations of externalizing should consider more robust measures of risk-related phenotypes
that assess various facets of both behavior (e.g., substance consumption, impulsive behaviors)
and attitudes (e.g., assessment of risk tolerance in both self and other).
In addition to such methodological limitations, the generalizability of our findings may
also be limited by the composition of our target sample. The DNS is comprised of largelyhealthy college students and community members and is not purposefully enriched for
externalizing features. This allows us to obtain a wide range of scores on behavioral measures of
impulsivity, delay discounting, and alcohol use that are comparable to the population at large,
but it does not allow us to use risk-taking PRS to predict current or future diagnosis of
externalizing disorders. Future investigations of the link between genomic liability for risktaking and the development of externalizing disorders in patient populations would better inform
downstream consequences. Additionally, for the current study, we performed all analyses in a
European-ancestry subset of the DNS, in order to match the ethnic composition of the discovery
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GWAS. While the majority of GWAS studies thus far have been conducted in European-ancestry
populations to control for potential confounding effects of population stratification on genetic
factors (Morales et al., 2018), it will be crucial for the field to improve its knowledge of how
genetic research applies across ethnicities and ancestries, as well as for future studies to recruit
diverse samples.

4.5

Conclusions

Externalizing disorders, characterized by sensation-seeking, impulse-control issues, and risktaking behavior, are common and have an immense socioeconomic and personal impact. Though
the literature suggests that they are highly-heritable, we know surprisingly little about the
etiologic mechanisms that underlie externalizing psychopathology, and, in turn, treatment and
prevention methods are limited. The current study investigated whether genomic liability for
externalizing, based upon a large-scale GWAS of risk tolerance, was associated with risk-related
behavioral and neural phenotypes in a community sample. Further, we explored differential gene
expression related to genomic liability and compared the predictive power of GWAS-based PRS
to that of gene-expression-based PRS. Here, we report null results with both approaches; as such,
future studies are needed to better understand how various factors that may have impacted our
results – including the reliability of task-fMRI, low-pass vs. deep phenotyping in genome-wide
studies, sample size, and statistical power – influence the utility of individual-differences
neuroscience and genetics research to inform our mechanistic understanding of complex
disorders.

33

References
Barratt, E. S., & Patton, J. H. (1995). Barratt Impulsiveness Scale-11. In Handbook of
psychiatric measures. https://doi.org/10.1037/t05661-000
Battle, A., Mostafavi, S., Zhu, X., Potash, J. B., Weissman, M. M., McCormick, C., … Koller, D.
(2014). Characterizing the genetic basis of transcriptome diversity through RNAsequencing of 922 individuals. Genome Research. https://doi.org/10.1101/gr.155192.113
Bogdan, R., Baranger, D. A. A., & Agrawal, A. (2018). Polygenic Risk Scores in Clinical
Psychology: Bridging Genomic Risk to Individual Differences. SSRN.
https://doi.org/10.1146/annurev-clinpsy-050817-084847
Brikell, I., Larsson, H., Lu, Y., Pettersson, E., Chen, Q., Kuja-Halkola, R., … Martin, J. (2018).
The contribution of common genetic risk variants for ADHD to a general factor of
childhood psychopathology. Molecular Psychiatry. https://doi.org/10.1038/s41380-0180109-2
Buckholtz, J. W., Treadway, M. T., Cowan, R. L., Woodward, N. D., Benning, S. D., Li, R., …
Zald, D. H. (2010). Mesolimbic dopamine reward system hypersensitivity in individuals
with psychopathic traits. Nature Neuroscience, 13(4), 419–421.
https://doi.org/10.1038/nn.2510
Button, T. M. M., Stallings, M. C., Rhee, S. H., Corley, R. P., Boardman, J. D., & Hewitt, J. K.
(2009). Perceived peer delinquency and the genetic predisposition for substance dependence
vulnerability. Drug and Alcohol Dependence.
https://doi.org/10.1016/j.drugalcdep.2008.08.014
Byrd, A. L., & Manuck, S. B. (2014). MAOA, childhood maltreatment, and antisocial behavior:
Meta-analysis of a gene-environment interaction. Biological Psychiatry.
https://doi.org/10.1016/j.biopsych.2013.05.004
Cai, N., Bigdeli, T. B., Kretzschmar, W., Lei, Y., Liang, J., Song, L., … Flint, J. (2015). Sparse
whole-genome sequencing identifies two loci for major depressive disorder. Nature.
https://doi.org/10.1038/nature14659
Carey, C. E., Knodt, A. R., Conley, E. D., Hariri, A. R., & Bogdan, R. (2017). Reward-Related
Ventral Striatum Activity Links Polygenic Risk for Attention-Deficit/Hyperactivity
Disorder to Problematic Alcohol Use in Young Adulthood. Biological Psychiatry:
Cognitive Neuroscience and Neuroimaging. https://doi.org/10.1016/j.bpsc.2016.10.003
Caspi, A., Houts, R. M., Belsky, D. W., & Goldman-mellor, S. J. (2015). The p Factor : One
General Psychopathology Factor in the. Clin Psychol Sci.
https://doi.org/10.1177/2167702613497473.The
Caulkins, J. P., Kasunic, A., & Lee, M. A. C. (2014). Societal burden of substance abuse.
International Public Health, 6(3), 269–282.
34

Delgado, M. R., Nystrom, L. E., Fissell, C., Noll, D. C., & Fiez, J. A. (2000). Tracking the
Hemodynamic Responses to Reward and Punishment in the Striatum. Journal of
Neurophysiology. https://doi.org/10.1152/jn.2000.84.6.3072
Dezhina, Z., Ranlund, S., Kyriakopoulos, M., Williams, S. C. R., & Dima, D. (2019). A
systematic review of associations between functional MRI activity and polygenic risk for
schizophrenia and bipolar disorder. Brain Imaging and Behavior.
https://doi.org/10.1007/s11682-018-9879-z
Dick, D. M., Bierut, L., Hinrichs, A., Fox, L., Bucholz, K. K., Kramer, J., … Foroud, T. (2006).
The role of GABRA2 in risk for conduct disorder and alcohol and drug dependence across
developmental stages. Behavior Genetics. https://doi.org/10.1007/s10519-005-9041-8
Dima, D., & Breen, G. (2015). Polygenic risk scores in imaging genetics: Usefulness and
applications. Journal of Psychopharmacology (Oxford, England), 29(8), 867–871.
https://doi.org/10.1177/0269881115584470
Doshi, J. A., Hodgkins, P., Kahle, J., Sikirica, V., Cangelosi, M. J., Setyawan, J., … Neumann,
P. J. (2012). Economic impact of childhood and adult attention-deficit/hyperactivity
disorder in the United States. Journal of the American Academy of Child and Adolescent
Psychiatry. https://doi.org/10.1016/j.jaac.2012.07.008
Duncan, L. E., & Keller, M. C. (2011). A critical review of the first 10 years of candidate geneby-environment interaction research in psychiatry. American Journal of Psychiatry.
https://doi.org/10.1176/appi.ajp.2011.11020191
Edenberg, H. J., & Foroud, T. (2014). Genetics of alcoholism. In Handbook of Clinical
Neurology. https://doi.org/10.1016/B978-0-444-62619-6.00032-X
Elliot, M. L., Knodt, A. R., Ireland, D., Morris, M. L., Poulton, R., Ramrakha, S., … Hariri, A.
R. (2019). Poor test-retest reliability of task-fMRI: New empirical evidence and a metaanalysis. BioRxiv.
Erk, S., Mohnke, S., Ripke, S., Lett, T. A., Veer, I. M., Wackerhagen, C., … Walter, H. (2017).
Functional neuroimaging effects of recently discovered genetic risk loci for schizophrenia
and polygenic risk profile in five RDoC subdomains. Translational Psychiatry.
https://doi.org/10.1038/tp.2016.272
Ferreira, M. A. R., O’Donovan, M. C., Meng, Y. A., Jones, I. R., Ruderfer, D. M., Jones, L., …
Craddock, N. (2008). Collaborative genome-wide association analysis supports a role for
ANK3 and CACNA1C in bipolar disorder. Nature Genetics, 40(9), 1056–1058.
https://doi.org/10.1038/ng.209
Gamazon, E. R., Wheeler, H. E., Shah, K. P., Mozaffari, S. V., Aquino-Michaels, K., Carroll, R.
J., … Im, H. K. (2015). A gene-based association method for mapping traits using reference
transcriptome data. Nature Genetics. https://doi.org/10.1038/ng.3367
Gluskin, B. S., & Mickey, B. J. (2016). Genetic variation and dopamine D2 receptor availability:
A systematic review and meta-analysis of human in vivo molecular imaging studies.
35

Translational Psychiatry. https://doi.org/10.1038/tp.2016.22
Green, L., Myerson, J., & Vanderveldt, A. (2014). Delay and probability discounting. In The
Wiley Blackwell handbook of operant and classical conditioning. (pp. 307–337).
https://doi.org/10.1002/9781118468135.ch13
Haber, S. N. (2011). Neuroanatomy of Reward: A View from the Ventral Striatum. Neurobiology
of Sensation and Reward.
Haber, S. N., & Knutson, B. (2010). The reward circuit: Linking primate anatomy and human
imaging. Neuropsychopharmacology. https://doi.org/10.1038/npp.2009.129
Han, X., Jovicich, J., Salat, D., van der Kouwe, A., Quinn, B., Czanner, S., … Fischl, B. (2006).
Reliability of MRI-derived measurements of human cerebral cortical thickness: The effects
of field strength, scanner upgrade and manufacturer. NeuroImage.
https://doi.org/10.1016/j.neuroimage.2006.02.051
Hariri, A. R. (2009). The Neurobiology of Individual Differences in Complex Behavioral Traits.
Annual Review of Neuroscience. https://doi.org/10.1146/annurev.neuro.051508.135335
Hicks, B. M., Krueger, R. F., Iacono, W. G., McGue, M., & Patrick, C. J. (2004). Family
transmission and heritability of externalizing disorders: A Twin-Family Study. Archives of
General Psychiatry, 61(9), 922–928. https://doi.org/10.1001/archpsyc.61.9.922
Hicks, B. M., South, S. C., DiRago, A. C., Iacono, W. G., & McGue, M. (2009). Environmental
adversity and increasing genetic risk for externalizing disorders. Archives of General
Psychiatry. https://doi.org/10.1001/archgenpsychiatry.2008.554
Howard, D. M., Adams, M. J., Clarke, T. K., Hafferty, J. D., Gibson, J., Shirali, M., …
McIntosh, A. M. (2019). Genome-wide meta-analysis of depression identifies 102
independent variants and highlights the importance of the prefrontal brain regions. Nature
Neuroscience. https://doi.org/10.1038/s41593-018-0326-7
Hu, Y., Shmygelska, A., Tran, D., Eriksson, N., Tung, J. Y., & Hinds, D. A. (2016). GWAS of
89,283 individuals identifies genetic variants associated with self-reporting of being a
morning person. Nature Communications. https://doi.org/10.1038/ncomms10448
Jones, H. J., Stergiakouli, E., Tansey, K. E., Hubbard, L., Heron, J., Cannon, M., … Zammit, S.
(2016). Phenotypic manifestation of genetic risk for schizophrenia during adolescence in the
general population. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2015.3058
Jovicich, J., Czanner, S., Greve, D., Haley, E., Van Der Kouwe, A., Gollub, R., … Dale, A.
(2006). Reliability in multi-site structural MRI studies: Effects of gradient non-linearity
correction on phantom and human data. NeuroImage.
https://doi.org/10.1016/j.neuroimage.2005.09.046
Karlsson Linnér, R., Biroli, P., Kong, E., Meddens, S. F. W., Wedow, R., Fontana, M. A., …
Beauchamp, J. P. (2019). Genome-wide association analyses of risk tolerance and risky
behaviors in over 1 million individuals identify hundreds of loci and shared genetic
36

influences. Nature Genetics. https://doi.org/10.1038/s41588-018-0309-3
Kendler, K. S. (2013). What psychiatric genetics has taught us about the nature of psychiatric
illness and what is left to learn. Molecular Psychiatry. https://doi.org/10.1038/mp.2013.50
Kessler, R. C., Aguilar-Gaxiola, S., Alonso, J., Chatterji, S., Lee, S., Ormel, J., … Wang, P. S.
(2009). The global burden of mental disorders: An update from the WHO World Mental
Health (WMH) surveys. Epidemiologia e Psichiatria Sociale.
https://doi.org/10.1017/S1121189X00001421
Kober, H., Mende-Siedlecki, P., Kross, E. F., Weber, J., Mischel, W., Hart, C. L., & Ochsner, K.
N. (2010). Prefrontal-striatal pathway underlies cognitive regulation of craving.
Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1007779107
Köhnke, M. D. (2008). Approach to the genetics of alcoholism: A review based on
pathophysiology. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2007.06.021
Krueger, R. F., Hicks, B. M., Patrick, C. J., Carlson, S. R., Iacono, W. G., & McGue, M. (2002).
Etiologic connections among substance dependence, antisocial behavior, and personality:
Modeling the externalizing spectrum. Journal of Abnormal Psychology, 111(3), 411–424.
https://doi.org/10.1037/0021-843X.111.3.411
Larsson, H., Chang, Z., D’Onofrio, B. M., & Lichtenstein, P. (2014). The heritability of
clinically diagnosed attention deficit hyperactivity disorder across the lifespan.
Psychological Medicine, 44(10), 2223–2229. https://doi.org/10.1017/S0033291713002493
Lee, S. H., Wray, N. R., Goddard, M. E., & Visscher, P. M. (2011). Estimating missing
heritability for disease from genome-wide association studies. American Journal of Human
Genetics, 88(3), 294–305. https://doi.org/10.1016/j.ajhg.2011.02.002
Li, B., Verma, S. S., Veturi, Y. C., Verma, A., Bradford, Y., Haas, D. W., & Ritchie, M. D.
(2018). Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene
expression. https://doi.org/10.1142/9789813235533_0041
Lonsdale, J., Thomas, J., Salvatore, M., Phillips, R., Lo, E., Shad, S., … Moore, H. F. (2013).
The Genotype-Tissue Expression (GTEx) project. Nature Genetics.
https://doi.org/10.1038/ng.2653
Loth, A. K., Drabick, D. A. G., Leibenluft, E., & Hulvershorn, L. A. (2014). Do childhood
externalizing disorders predict adult depression? A meta-analysis. Journal of Abnormal
Child Psychology, 42(7), 1103–1113. https://doi.org/10.1007/s10802-014-9867-8
Mazaika, Whitfield-Gabrieli, & Reiss…, A. (2007). Artifact repair for fMRI data from high
motion clinical subjects. Annual Meeting of the ….
Morales, J., Welter, D., Bowler, E. H., Cerezo, M., Harris, L. W., McMahon, A. C., …
MacArthur, J. A. L. (2018). A standardized framework for representation of ancestry data in
genomics studies, with application to the NHGRI-EBI GWAS Catalog. Genome Biology.
https://doi.org/10.1186/s13059-018-1396-2
37

Myerson, J., Green, L., & Warusawitharana, M. (2001). Area under the curve as a measure of
discounting. Journal of the Experimental Analysis of Behavior, 76(2), 235–243.
https://doi.org/10.1901/jeab.2001.76-235
Nikolova, Y. S., Knodt, A. R., Radtke, S. R., & Hariri, A. R. (2016). Divergent responses of the
amygdala and ventral striatum predict stress-related problem drinking in young adults:
Possible differential markers of affective and impulsive pathways of risk for alcohol use
disorder. Molecular Psychiatry, 21(3), 348–356. https://doi.org/10.1038/mp.2015.85
Pasche, B., & Yi, N. (2010). Candidate gene association studies: Successes and failures. Current
Opinion in Genetics and Development. https://doi.org/10.1016/j.gde.2010.03.006
Purcell, S. (2017). PLINK: Whole genome association analysis toolset.
Reef, J., Diamantopoulou, S., Van Meurs, I., Verhulst, F. C., & Van Der Ende, J. (2011).
Developmental trajectories of child to adolescent externalizing behavior and adult DSM-IV
disorder: Results of a 24-year longitudinal study. Social Psychiatry and Psychiatric
Epidemiology, 46(12), 1233–1241. https://doi.org/10.1007/s00127-010-0297-9
Reinert, D. F., & Allen, J. P. (2007). The alcohol use disorders identification test: An update of
research findings. Alcoholism: Clinical and Experimental Research.
https://doi.org/10.1111/j.1530-0277.2006.00295.x
Rietveld, C. A., Medland, S. E., Derringer, J., Yang, J., Esko, T., Martin, N. W., … Koellinger,
P. D. (2013). GWAS of 126,559 individuals identifies genetic variants associated with
educational attainment. Science. https://doi.org/10.1126/science.1235488
Riglin, L., Collishaw, S., Richards, A., Thapar, A. K., Maughan, B., O’Donovan, M. C., &
Thapar, A. (2017). Schizophrenia risk alleles and neurodevelopmental outcomes in
childhood: a population-based cohort study. The Lancet Psychiatry.
https://doi.org/10.1016/S2215-0366(16)30406-0
Ripke, S., Wray, N. R., Lewis, C. M., Hamilton, S. P., Weissman, M. M., Breen, G., … Sullivan,
P. F. (2012). A mega-analysis of genome-wide association studies for major depressive
disorder. Molecular Psychiatry. https://doi.org/10.1038/mp.2012.21
Rodgers, S., Müller, M., Rössler, W., Castelao, E., Preisig, M., & Ajdacic-Gross, V. (2015).
Externalizing disorders and substance use: empirically derived subtypes in a populationbased sample of adults. Social Psychiatry and Psychiatric Epidemiology, 50(1), 7–17.
https://doi.org/10.1007/s00127-014-0898-9
Rushworth, M. F. S., Noonan, M. A. P., Boorman, E. D., Walton, M. E., & Behrens, T. E.
(2011). Frontal Cortex and Reward-Guided Learning and Decision-Making. Neuron.
https://doi.org/10.1016/j.neuron.2011.05.014
Sacks, J. J., Gonzales, K. R., Bouchery, E. E., Tomedi, L. E., & Brewer, R. D. (2015). 2010
National and State Costs of Excessive Alcohol Consumption. American Journal of
Preventive Medicine. https://doi.org/10.1016/j.amepre.2015.05.031
38

Salvatore, J. E., Edwards, A. C., McClintick, J. N., Bigdeli, T. B., Adkins, A., Aliev, F., … Dick,
D. M. (2015). Genome-wide association data suggest ABCB1 and immune-related gene sets
may be involved in adult antisocial behavior. Translational Psychiatry.
https://doi.org/10.1038/tp.2015.36
Sanchez-Roige, S., Palmer, A. A., Fontanillas, P., Elson, S. L., Adams, M. J., Howard, D. M., …
Wilson, C. H. (2019). Genome-wide association study meta-analysis of the alcohol use
disorders identification test (AUDIT) in two population-based cohorts. American Journal of
Psychiatry. https://doi.org/10.1176/appi.ajp.2018.18040369
Saunders, J. B., Aasland, O. G., Babor, T. F., De La Fuente, J. R., & Grant, M. (1993).
Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO
Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption‐II.
Addiction. https://doi.org/10.1111/j.1360-0443.1993.tb02093.x
Scheres, A., Milham, M. P., Knutson, B., & Castellanos, F. X. (2007). Ventral Striatal
Hyporesponsiveness During Reward Anticipation in Attention-Deficit/Hyperactivity
Disorder. Biological Psychiatry. https://doi.org/10.1016/j.biopsych.2006.04.042
Slutske, W. S., Heath, A. C., Dinwiddie, S. H., Madden, P. A. F., Bucholz, K. K., Dunne, M. P.,
… Martin, N. G. (1998). Common genetic risk factors for conduct disorder and alcohol
dependence. Journal of Abnormal Psychology. https://doi.org/10.1037/0021843X.107.3.363
Sullivan, P. F. (2010). The Psychiatric GWAS Consortium: Big science comes to psychiatry.
Neuron. https://doi.org/10.1016/j.neuron.2010.10.003
van der Laan, L. N., Barendse, M. E. A., Viergever, M. A., & Smeets, P. A. M. (2016). Subtypes
of trait impulsivity differentially correlate with neural responses to food choices.
Behavioural Brain Research. https://doi.org/10.1016/j.bbr.2015.09.026
Verhulst, B., Neale, M. C., & Kendler, K. S. (2015). The heritability of alcohol use disorders: A
meta-analysis of twin and adoption studies. Psychological Medicine.
https://doi.org/10.1017/S0033291714002165
Visscher, P. M., Brown, M. A., McCarthy, M. I., & Yang, J. (2012). Five years of GWAS
discovery. American Journal of Human Genetics.
https://doi.org/10.1016/j.ajhg.2011.11.029
Visscher, P. M., Wray, N. R., Zhang, Q., Sklar, P., McCarthy, M. I., Brown, M. A., & Yang, J.
(2017). 10 Years of GWAS Discovery: Biology, Function, and Translation. American
Journal of Human Genetics. https://doi.org/10.1016/j.ajhg.2017.06.005
Vollebergh, W. A. M., Iedema, J., Bijl, R. V., De Graaf, R., Smit, F., & Ormel, J. (2001). The
structure and stability of common mental disorders: The NEMESIS Study. Archives of
General Psychiatry. https://doi.org/10.1001/archpsyc.58.6.597
Von Rhein, D., Cools, R., Zwiers, M. P., Van Der Schaaf, M., Franke, B., Luman, M., …
Buitelaar, J. (2015). Increased neural responses to reward in adolescents and young adults
39

with attention-deficit/hyperactivity disorder and their unaffected siblings. Journal of the
American Academy of Child and Adolescent Psychiatry.
https://doi.org/10.1016/j.jaac.2015.02.012
Walters, R. K., Polimanti, R., Johnson, E. C., McClintick, J. N., Adams, M. J., Adkins, A. E., …
Agrawal, A. (2018). Transancestral GWAS of alcohol dependence reveals common genetic
underpinnings with psychiatric disorders. Nature Neuroscience.
https://doi.org/10.1038/s41593-018-0275-1
Weeland, J., Overbeek, G., de Castro, B. O., & Matthys, W. (2015). Underlying Mechanisms of
Gene–Environment Interactions in Externalizing Behavior: A Systematic Review and
Search for Theoretical Mechanisms. Clinical Child and Family Psychology Review.
https://doi.org/10.1007/s10567-015-0196-4
Weiland, B. J., Heitzeg, M. M., Zald, D., Cummiford, C., Love, T., Zucker, R. A., & Zubieta, J.
K. (2014). Relationship between impulsivity, prefrontal anticipatory activation, and striatal
dopamine release during rewarded task performance. Psychiatry Research - Neuroimaging.
https://doi.org/10.1016/j.pscychresns.2014.05.015
Wray, N. R., Ripke, S., Mattheisen, M., Trzaskowski, M., Byrne, E. M., Abdellaoui, A., …
Sullivan, P. F. (2018). Genome-wide association analyses identify 44 risk variants and
refine the genetic architecture of major depression. Nature Genetics.
https://doi.org/10.1038/s41588-018-0090-3

40

Supplemental Materials
Supplemental Table 1. DNS Psychiatric Diagnosis Data
Diagnosis
Major Depressive Disorder
Bipolar Disorder
Panic Disorder (no Agoraphobia)
Panic Disorder (with Agoraphobia)
Social Anxiety Disorder
Obsessive Compulsive Disorder
Alcohol Abuse/Dependence Disorder
Post-Traumatic Stress Disorder

Number of Participants
28 (5.32%)
16 (0.03%)
14 (0.03%)
12 (0.02%)
5 (0.01%)
6 (0.01%)
67 (12.7%)
0 (0.0%)

Supplemental Figure 1. Distribution of Ventral Striatal Activation to Card-Guessing Task
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Supplemental Table 2. Main Effects of Risk-Tolerance PRS on Structure of Risk-Related
Cortical Regions
ROSTRAL
ACC
PRS
p-threshold
0.0001
0.001
0.01
0.05
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1
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β

p

β

p

β

p
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0.5678
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0.7279
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0.4860

0.3265

0.2895

0.2695

0.3844

0.5805
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0.2320

0.4450

-0.0562

0.8938

0.1091

0.7964

-0.0620
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-0.1376

0.7400

-0.0728

0.8849

-0.1626
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-0.7476
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0.2061

0.6770

-0.0450

0.8996

-0.2685

0.4537
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Supplemental Table 3. Main Effects of Risk-Tolerance PRS on Structure of Risk-Related
Subcortical Regions
PARAHIPPOCAMPUS
PRS
p-threshold
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0.6716

0.0757
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0.3444
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